SJS Investment Consulting’s Pacira BioSciences PCRX Stock Holding History

SJS Investment Consulting’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.41K	Buy	176 +28	+19%	+$709	﹤0.01%	1797
2026 Q2	$3.76K	Buy	+148	New	+$3.5K	﹤0.01%	1500
2024 Q3	–	Sell	-5	Closed	-$144	–	1700
2024 Q2	$144	Hold	5	–	–	﹤0.01%	1554
2024 Q1	$147	Hold	5	–	–	﹤0.01%	1531
2023 Q4	$169	Buy	5 +1	+25%	+$29	﹤0.01%	1491
2023 Q3	$123	Sell	4 -1	-20%	-$36	﹤0.01%	1519
2023 Q2	$201	Sell	5 -1	-17%	-$41	﹤0.01%	1406
2023 Q1	$245	Buy	6 +1	+20%	+$40	﹤0.01%	1319
2022 Q4	$193	Buy	5 +1	+25%	+$49	﹤0.01%	1419
2022 Q3	$0	Buy	+4	New	+$222	﹤0.01%	1416
2022 Q1	$12K	Buy	163 +1	+0.6%	+$67	﹤0.01%	371
2021 Q4	$10K	Buy	+162	New	+$8.93K	﹤0.01%	375

Other funds holding PCRX

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Impax Asset Management Group London, United Kingdom $13B AUM 14.15% 1-Year Est. Return

Gagnon Securities New York $577M AUM 61.61% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bridge City Capital Lake Oswego, Oregon $480M AUM 47.16% 1-Year Est. Return

SJS Investment Consulting's PCRX Position: Q3 2026 in Review

SJS Investment Consulting increased its Pacira BioSciences (PCRX) stake by 19% in Q3 2026, buying an estimated $709 and bringing the position to 176 shares worth $4.41K. The position accounts for ﹤0.01% of the portfolio, ranked #1797.

SJS Investment Consulting first reported a position in PCRX in Q4 2021 and has held it in 12 quarters since. The position peaked at $12K in Q1 2022. 137 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

SJS Investment Consulting held 176 shares of Pacira BioSciences worth $4.41K as of Q3 2026.
SJS Investment Consulting bought 28 Pacira BioSciences shares in Q3 2026, an estimated $709.
Pacira BioSciences made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #1797 holding.
SJS Investment Consulting first reported a position in Pacira BioSciences in Q4 2021 and has held it in 12 quarters since.
SJS Investment Consulting's Pacira BioSciences position peaked at $12K in Q1 2022.
137 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.